Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theriva Biologics ( (TOVX) ) has issued an update.
On September 28, 2025, Theriva Biologics‘ Board of Directors approved a restructuring plan to focus on business development and licensing activities, particularly for clinical trials of its lead product, VCN-01, targeting metastatic pancreatic ductal adenocarcinoma and retinoblastoma. As part of this plan, the company reduced its workforce by 32% on September 30, 2025, to reallocate resources towards these strategic objectives, expecting to save $2 million annually and extend its cash runway into the second quarter of 2026.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Theriva Biologics, Inc. operates in the biotechnology industry, focusing on the development of oncolytic viruses for cancer treatment. Its lead product candidate, VCN-01, is a clinical-stage oncolytic human adenovirus designed for tumor-selective replication and enzyme expression, aimed at treating pancreatic cancer and retinoblastoma.
Average Trading Volume: 547,413
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.86M
Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.